These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 11859270

  • 21. [The effect of lovastatin on the development of adriamycin nephropathy in rats].
    Tesar V, Zima T, Poledne R, Stejskalová A, Tĕmínová J, Stípek S.
    Sb Lek; 1995; 96(1):35-42. PubMed ID: 8711364
    [Abstract] [Full Text] [Related]

  • 22. Hepatic morphological alterations, glycogen content and cytochrome P450 activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME).
    Tarsitano CA, Paffaro VA, Pauli JR, da Silva GH, Saad MJ, Salgado I, da Cruz-Höfling MA, Hyslop S.
    Cell Tissue Res; 2007 Jul; 329(1):45-58. PubMed ID: 17436021
    [Abstract] [Full Text] [Related]

  • 23. Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment.
    Proesmans W, Van Dyck M, Devriendt K.
    Nephrol Dial Transplant; 2009 Apr; 24(4):1335-8. PubMed ID: 19147669
    [Abstract] [Full Text] [Related]

  • 24. ACE inhibitor and AT1 antagonist stimulate duodenal HCO3- secretion mediated by a common pathway - involvement of PG, NO and bradykinin.
    Aihara E, Kagawa S, Hayashi M, Takeuchi K.
    J Physiol Pharmacol; 2005 Sep; 56(3):391-406. PubMed ID: 16204762
    [Abstract] [Full Text] [Related]

  • 25. Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system.
    Inserra F, Basso N, Ferder M, Userpater M, Stella I, Paglia N, Inserra P, Tenembaum D, Ferder L.
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):341-6. PubMed ID: 19574289
    [Abstract] [Full Text] [Related]

  • 26. Effect of losartan and enalapril on cognitive deficit caused by Goldblatt induced hypertension.
    Srinivasan J, Jayadev S, Kumaran D, Ahamed KF, Suresh B, Ramanathan M.
    Indian J Exp Biol; 2005 Mar; 43(3):241-6. PubMed ID: 15816410
    [Abstract] [Full Text] [Related]

  • 27. Effectiveness of dietary protein augmentation associated with angiotensin-converting enzyme inhibition in the management of the nephrotic syndrome.
    Garini G, Mazzi A, Allegri L, Buzio C, Borghetti A.
    Miner Electrolyte Metab; 1996 Mar; 22(1-3):123-7. PubMed ID: 8676802
    [Abstract] [Full Text] [Related]

  • 28. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y, Taura K, Taguchi T, Furusu A, Kohno S.
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [Abstract] [Full Text] [Related]

  • 29. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 30. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE.
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [Abstract] [Full Text] [Related]

  • 31. Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats.
    Alvarez Y, Pérez-Girón JV, Hernanz R, Briones AM, García-Redondo A, Beltrán A, Alonso MJ, Salaices M.
    J Pharmacol Exp Ther; 2007 Apr; 321(1):381-8. PubMed ID: 17244722
    [Abstract] [Full Text] [Related]

  • 32. New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model.
    Richter M, Skupin M, Grabs R, Schramm D, Richter H, Olbrich HG.
    J Heart Lung Transplant; 2000 Nov; 19(11):1047-55. PubMed ID: 11077221
    [Abstract] [Full Text] [Related]

  • 33. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats.
    de Cavanagh EM, Piotrkowski B, Basso N, Stella I, Inserra F, Ferder L, Fraga CG.
    FASEB J; 2003 Jun; 17(9):1096-8. PubMed ID: 12709417
    [Abstract] [Full Text] [Related]

  • 34. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.
    Yavuz D, Koç M, Toprak A, Akpinar I, Velioğlu A, Deyneli O, Haklar G, Akalin S.
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):197-203. PubMed ID: 14608527
    [Abstract] [Full Text] [Related]

  • 35. [The additive antiproteinuric effect of Enalapril and Losartan to normotensive patients with pathology proteinuria].
    Liern M, Dieguez SM, De Reyes V, Vallejos G, Canepa C.
    Nefrologia; 2004 Sep; 24(6):553-8. PubMed ID: 15683027
    [Abstract] [Full Text] [Related]

  • 36. Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction.
    Onodera H, Matsunaga T, Tamura Y, Maeda N, Higuma T, Sasaki S, Mori Y, Yoshimachi F, Ishizaka H, Hanada H, Osanai T, Okumura K.
    Am Heart J; 2005 Oct; 150(4):689. PubMed ID: 16209966
    [Abstract] [Full Text] [Related]

  • 37. Insulin and losartan reduce proteinuria and renal hypertrophy in the pregnant diabetic rat.
    Natif N, Sclarovsky-Benjaminov F, Van Dijk DJ, Sulkes J, Gafter U, Boner G, Erman A.
    J Lab Clin Med; 2003 Sep; 142(3):166-71. PubMed ID: 14532904
    [Abstract] [Full Text] [Related]

  • 38. In vivo visualization of the antialbuminuric effects of the angiotensin-converting enzyme inhibitor enalapril.
    Schießl IM, Kattler V, Castrop H.
    J Pharmacol Exp Ther; 2015 May; 353(2):299-306. PubMed ID: 25680709
    [Abstract] [Full Text] [Related]

  • 39. ACE inhibition restores the vasodilator potency of the endothelium-derived relaxing factor, L-S-nitrosocysteine, in conscious Spontaneously Hypertensive rats.
    Lewis SJ, Hashmi-Hill MP, Owen JR, Sandock K, Robertson TP, Bates JN.
    Vascul Pharmacol; 2006 Jun; 44(6):491-507. PubMed ID: 16713366
    [Abstract] [Full Text] [Related]

  • 40. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.